Highlights Comera Life Sciences Holdings, Inc.

Equities

CMRA

US20037C1080

Market Closed - OTC Markets Other stock markets 10:49:23 28/05/2024 pm IST			5-day change	1st Jan Change
0.0229 ^USD	-21.71%		-21.84%	-58.36%

30/01	Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes	CI
30/01	Comera Life Sciences Holdings, Inc. Announces Changes to Its Board	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q3 Revenue $136,310	09/11	MT
Comera Life Sciences Holdings, Inc. Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities	16/23/16	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q2 Revenue $315.1M	10/23/10	MT
Comera Life Sciences Holdings, Inc. Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore(TM) Platform	08/23/08	CI
Comera Life Sciences Holdings, Inc. Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients	20/23/20	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q1 Revenue $392.9M	11/23/11	MT
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q4 Revenue $156,120	16/23/16	MT
North American Morning Briefing : Payrolls Shocker, China Spat to Weigh on Stocks	06/23/06	DJ
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q3 Revenue $234,922	10/22/10	MT
Comera Life Sciences Holdings, Inc. Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study	18/22/18	CI
Comera Life Sciences Holdings, Inc. Expands Woburn Operations	04/22/04	CI
Comera Life Sciences : Provides Business Highlights and Reports Financial Results for the Second Quarter 2022 - Form 8-K	16/22/16	PU
Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit	11/22/11	CI
Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient	13/22/13	CI
Comera Life Sciences Secures US Patent Related to Its SQore Platform	22/22/22	MT
Comera Life Sciences, Inc. completed the acquisition of OTR Acquisition Corp. from OTR Acquisition Sponsor LLC, Karpus Management Inc, Polar Asset Management Partners Inc., Hudson Bay Capital Management LP and others in a reverse merger transaction.	19/22/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Comera Life Sciences Holdings, Inc.

Equities

CMRA

US20037C1080

Highlights

Filters